Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy
Stephen L. Abrams(East Carolina University), James A. McCubrey(East Carolina University), Franca Stivala(University of Catania), Massimo Libra(University of Catania), Marco Donia(University of Copenhagen), Alberto M. Martelli(University of Bologna), Ferdinando Nicoletti(University of Catania), John G. Shelton(Greenville College), Jörg Bäsecke(University of Göttingen), Linda S. Steelman(East Carolina University), William H. Chappell(University of North Carolina at Chapel Hill)
Cited by 27
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508